Compare PDS & PCRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | PDS | PCRX |
|---|---|---|
| Founded | 1951 | 2006 |
| Country | Canada | United States |
| Employees | N/A | N/A |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 918.1M | 1.0B |
| IPO Year | 1998 | 2010 |
| Metric | PDS | PCRX |
|---|---|---|
| Price | $93.93 | $22.74 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 3 | 5 |
| Target Price | ★ $122.33 | $37.20 |
| AVG Volume (30 Days) | 122.6K | ★ 593.8K |
| Earning Date | 04-29-2026 | 05-07-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 107.44 |
| EPS | N/A | ★ 0.16 |
| Revenue | N/A | ★ $541,533,000.00 |
| Revenue This Year | $6.09 | $6.78 |
| Revenue Next Year | $2.10 | $8.54 |
| P/E Ratio | $884.15 | ★ $141.88 |
| Revenue Growth | N/A | ★ 26.04 |
| 52 Week Low | $36.20 | $18.80 |
| 52 Week High | $103.80 | $27.99 |
| Indicator | PDS | PCRX |
|---|---|---|
| Relative Strength Index (RSI) | 50.77 | 50.06 |
| Support Level | $85.27 | $22.57 |
| Resistance Level | $103.80 | $23.94 |
| Average True Range (ATR) | 3.83 | 0.90 |
| MACD | -0.87 | -0.03 |
| Stochastic Oscillator | 25.34 | 52.38 |
Precision Drilling Corp is a provider of contract drilling and completion and production services to oil and natural gas exploration and production companies in Canada, the United States, and certain international locations. Contract Drilling Services include drilling rigs, procurement and distribution of oilfield supplies, and the manufacture, sale and repair of drilling equipment. Completion and Production Services include service rigs, oilfield equipment rental, and camp and catering services.
Pacira BioSciences Inc is a provider of non-opioid pain management and regenerative health solutions dedicated to advancing and improving outcomes for healthcare practitioners and their patients. The company's commercialized non-opioid treatments: EXPAREL a long-acting, local analgesic currently approved for postsurgical pain management; ZILRETTA, an extended-release, intra-articular, corticosteroid injection indicated for the management of osteoarthritis; and iovera, a novel, handheld device for delivering immediate, long-acting, drug-free pain control using precise, controlled doses of cold temperature to a targeted nerve. In addition, it is developing PCRX-201 (enekinragene inzadenovec), a novel gene therapy vector platform for the treatment of osteoarthritis of the knee.